Sundström J, Bodegard J, Bollmann A, et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: the CaReMe CKD study. Lancet Reg Health Eur. 2022;20:100438.
Article PubMed PubMed Central Google Scholar
Fraser SD, Blakeman T. Chronic kidney disease: identification and management in primary care. Pragmat Obs Res. 2016;7:21–32.
PubMed PubMed Central Google Scholar
Chu CD, McCulloch CE, Banerjee T, et al. CKD awareness among US adults by future risk of kidney failure. Am J Kidney Dis. 2020;76(2):174–83.
Article PubMed PubMed Central Google Scholar
Tangri N, Moriyama T, Schneider MP, et al. Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL-CKD study. BMJ Open. 2023;13(5):e067386.
Article PubMed PubMed Central Google Scholar
Nichols GA, Déruaz-Luyet A, Brodovicz KG, Kimes TM, Rosales AG, Hauske SJ. Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs without type 2 diabetes. BMC Nephrol. 2020;21(1):167.
Article PubMed PubMed Central CAS Google Scholar
Tangri N, Alvarez CS, Arnold M, Barone S, Cebrián A, Chen H, et al. Suboptimal monitoring and management in patients with unrecorded stage 3 chronic kidney disease in real-world settings: insights from REVEAL-CKD. Eur J Clin Invest. 2024. https://doi.org/10.1111/eci.14282.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117–S314.
Tangri N, Peach EJ, Franzén S, Barone S, Kushner PR. Patient management and clinical outcomes associated with a recorded diagnosis of stage 3 chronic kidney disease: the REVEAL-CKD study. Adv Ther. 2023;40(6):2869–85.
Article PubMed PubMed Central CAS Google Scholar
Carney EF. The impact of chronic kidney disease on global health. Nat Rev Nephrol. 2020;16(5):251.
Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339–52.
Verberne WR, Das-Gupta Z, Allegretti AS, et al. Development of an international standard set of value-based outcome measures for patients with chronic kidney disease: a report of the International Consortium for Health Outcomes Measurement (ICHOM) CKD Working Group. Am J Kidney Dis. 2019;73(3):372–84.
Zoccali C, Mark PB, Sarafidis P, et al. Diagnosis of cardiovascular disease in patients with chronic kidney disease. Nat Rev Nephrol. 2023;19(11):733–46.
Szlagor M, Dybiec J, Młynarska E, Rysz J, Franczyk B. Chronic kidney disease as a comorbidity in heart failure. Int J Mol Sci. 2023;24(3):2988.
Article PubMed PubMed Central CAS Google Scholar
MacRae C, Mercer SW, Guthrie B, Henderson D. Comorbidity in chronic kidney disease: a large cross-sectional study of prevalence in Scottish primary care. Br J Gen Pract. 2021;71(704):e243–9.
Article PubMed PubMed Central Google Scholar
Chadban S, Esposito C, Rangaswami J, Wu M-S, Hull R, Elsayed H, et al. #4529 PACE-CKD: Financial burden and work productivity of patients with CKD and caregivers: results from a US survey. Nephrol Dial Transplant. 2023;38(Suppl 1):4529.
Esposito C, Chadban S, Rangaswami J, et al. #3990 PACE-CKD: Health-related quality of life of patients with CKD and caregivers: results from a US survey. Nephrol Dial Transplant. 2023;38(Suppl 1):3990.
Carrero J, Pollock C, Kanda E, et al. #3393 Patient-reported outcomes in early versus advanced chronic kidney disease: evidence from baseline data in the discover CKD prospective study. Nephrol Dial Transplant. 2023;38.
Tummalapalli SL, Powe NR, Keyhani S. Trends in quality of care for patients with CKD in the United States. Clin J Am Soc Nephrol. 2019;14(8):1142–50.
Article PubMed PubMed Central Google Scholar
Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12(1):7–11.
Jha V, Al-Ghamdi SMG, Li G, et al. Global economic burden associated with chronic kidney disease: a pragmatic review of medical costs for the inside CKD research programme. Adv Ther. 2023;40(10):4405–20.
Article PubMed PubMed Central Google Scholar
World Health Organization: Reducing noncommunicable diseases: a signature roadmap for the WHO European Region. https://www.who.int/europe/publications/i/item/WHO-EURO-2022-6620-46386-67147. Accessed July 2023.
ISN Global Kidney Health Atlas. https://www.theisn.org/initiatives/global-kidney-health-atlas/. Accessed 2023.
Francis A, Harhay MN, Ong ACM, et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024;20:473.
Khunti K, Sathanapally H, Mountain P. Multiple long term conditions, multimorbidity, and co-morbidities: we should reconsider the terminology we use. BMJ. 2023;383:2327.
Nee R, Yuan CM, Narva AS, Yan G, Norris KC. Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease. Nephrol Dial Transplant. 2023;38(3):532–41.
Sperati CJ, Soman S, Agrawal V, et al. Primary care physicians’ perceptions of barriers and facilitators to management of chronic kidney disease: a mixed methods study. PLoS ONE. 2019;14(8):e0221325.
Article PubMed PubMed Central CAS Google Scholar
Khunti K, Jabbour S, Cos X, et al. Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes: barriers and solutions for improving uptake in routine clinical practice. Diabetes Obes Metab. 2022;24(7):1187–96.
Article PubMed PubMed Central CAS Google Scholar
Delgado C, Baweja M, Crews DC, et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease. Am J Kidney Dis. 2022;79(2):268–88.e1.
Madero M, Chertow GM, Mark PB. SGLT2 inhibitor use in chronic kidney disease: supporting cardiovascular, kidney, and metabolic health. Kidney Med. 2024;6(8):100851.
Heerspink HJL, Jongs N, Chertow GM, et al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):743–54.
Article PubMed CAS Google Scholar
Komenda P, Ferguson TW, Macdonald K, et al. Cost-effectiveness of primary screening for CKD: a systematic review. Am J Kidney Dis. 2014;63(5):789–97.
Cusick MM, Tisdale RL, Chertow GM, Owens DK, Goldhaber-Fiebert JD. Population-wide screening for chronic kidney disease: a cost-effectiveness analysis. Ann Intern Med. 2023;176(6):788–97.
Article PubMed PubMed Central Google Scholar
Mancia G, Kreutz R, Brunström M, et al. ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hyperten. 2023. https://doi.org/10.1097/HJH.0000000000003480.
Mark PB, Sarafidis P, Ekart R, et al. SGLT2i for evidence based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA. Nephrol Dial Transplant. 2023;38(11):2444–55.
Schroeder EB, Yang X, Thorp ML, et al. Predicting 5-year risk of RRT in stage 3 or 4 CKD: development and external validation. Clin J Am Soc Nephrol. 2017;12(1):87–94.
Article PubMed CAS Google Scholar
Grams ME, Brunskill NJ, Ballew SH, et al. The kidney failure risk equation: evaluation of novel input variables including eGFR estimated using the CKD-EPI 2021 equation in 59 cohorts. J Am Soc Nephrol. 2023;34(3):482–94.
Article PubMed PubMed Central Google Scholar
Major RW, Shepherd D, Medcalf JF, Xu G, Gray LJ, Brunskill NJ. The kidney failure risk equation for prediction of end stage renal disease in UK primary care: an external validation and clinical impact projection cohort study. PLoS Med. 2019;16(11):e1002955.
Comments (0)